Biomarkers in Alzheimer Disease and Other Dementias: What’s Next into Pathophysiology to Support Clinical Practice and Drug Development
Neurodegenerative diseases are a heterogeneous group of disorders characterized by gradual progressive neuronal loss in the central nervous system [...]
Main Author: | Anastasia Bougea |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1648-9144/58/10/1374 |
Similar Items
-
Editorial: Body fluid biomarkers in neurodegenerative studies: Novel insights into pathophysiology to support clinical practice and drug development
by: Anastasia Bougea, et al.
Published: (2023-01-01) -
Non-Motor Disorders in Parkinson Disease and Other Parkinsonian Syndromes
by: Anastasia Bougea, et al.
Published: (2024-02-01) -
Editorial: Neurotoxins in Alzheimer's disease and other dementias
by: Alexandre Henriques, et al.
Published: (2024-01-01) -
The Role of Cerebrospinal Fluid Biomarkers in Dementia and Other Related Neurodegenerative Disorders
by: George P. Paraskevas
Published: (2022-05-01) -
Stroke, Dementia, and Atrial Fibrillation: From Pathophysiologic Association to Pharmacological Implications
by: Vincenzo Russo, et al.
Published: (2020-05-01)